A Novel Benzopyrone Derivative from Streptomyces chrestomyceticus ADP4 Inhibits Growth and Virulence Factors of Candida albicans.

IF 2.6 3区生物学 Q3 MICROBIOLOGY Current Microbiology Pub Date : 2025-03-18 DOI:10.1007/s00284-025-04169-2

Radha Singh, Jyoti Shukla, Mohd Ali, Ashok K Dubey

{"title":"A Novel Benzopyrone Derivative from Streptomyces chrestomyceticus ADP4 Inhibits Growth and Virulence Factors of Candida albicans.","authors":"Radha Singh, Jyoti Shukla, Mohd Ali, Ashok K Dubey","doi":"10.1007/s00284-025-04169-2","DOIUrl":null,"url":null,"abstract":"Antimicrobial resistance (AMR) poses a serious threat to human health globally. Expeditious discovery and development of new drugs has become indispensable for addressing this challenge. In this context, a novel benzopyrone derivative, designated as 82B1, has been isolated from S. chrestomyceticus strain ADP4. This compound exhibited significant inhibitory activity against different Candida species including C. albicans, C. tropicalis, C. krusei, C. parapsilosis and C. auris with minimum inhibitory concentration (MIC90) values in the concentration range of 25-125 µg/mL. The structure of 82B1 was elucidated through analyses of the spectral data obtained using liquid chromatography-tandem mass spectrometry (LCMS/MS), Nuclear Magnetic Resonance (NMR), Fourier Transform Infrared Spectroscopy (FTIR) and Ultraviolet (UV) spectroscopy, that led to its identity as 7, 13, 14-trihydroxy-6H-benzo-[c]-chromen-6-one8-[1'β-carboxycyclopentanyl]-2'β-[8'β-ethylcyclopentane]. It significantly inhibited the major virulence factors of C. albicans such as yeast to hyphae transition, biofilm formation, and secretion of hydrolytic enzymes at its subinhibitory concentrations. It did not display cytotoxicity on human hepatoblastoma cell line (HepG2 cells), signifying its potential as a candidate for anti-Candida drug development.","PeriodicalId":11360,"journal":{"name":"Current Microbiology","volume":"82 5","pages":"201"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s00284-025-04169-2","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Antimicrobial resistance (AMR) poses a serious threat to human health globally. Expeditious discovery and development of new drugs has become indispensable for addressing this challenge. In this context, a novel benzopyrone derivative, designated as 82B1, has been isolated from S. chrestomyceticus strain ADP4. This compound exhibited significant inhibitory activity against different Candida species including C. albicans, C. tropicalis, C. krusei, C. parapsilosis and C. auris with minimum inhibitory concentration (MIC₉₀) values in the concentration range of 25-125 µg/mL. The structure of 82B1 was elucidated through analyses of the spectral data obtained using liquid chromatography-tandem mass spectrometry (LCMS/MS), Nuclear Magnetic Resonance (NMR), Fourier Transform Infrared Spectroscopy (FTIR) and Ultraviolet (UV) spectroscopy, that led to its identity as 7, 13, 14-trihydroxy-6H-benzo-[c]-chromen-6-one8-[1'β-carboxycyclopentanyl]-2'β-[8'β-ethylcyclopentane]. It significantly inhibited the major virulence factors of C. albicans such as yeast to hyphae transition, biofilm formation, and secretion of hydrolytic enzymes at its subinhibitory concentrations. It did not display cytotoxicity on human hepatoblastoma cell line (HepG2 cells), signifying its potential as a candidate for anti-Candida drug development.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

一种新型苯并吡酮衍生物对白色念珠菌生长和毒力因子的抑制作用。

抗微生物药物耐药性（AMR）对全球人类健康构成严重威胁。快速发现和开发新药已成为应对这一挑战不可或缺的手段。在此背景下，一种新的苯并吡酮衍生物，命名为82B1，已从葡萄球菌chrestomyceticus菌株ADP4中分离出来。该化合物对白色念珠菌、热带念珠菌、克鲁西念珠菌、副枯枝念珠菌和耳念珠菌均有明显的抑制作用，最低抑菌浓度（MIC90）在25 ~ 125µg/mL之间。通过液相色谱-串联质谱（LCMS/MS）、核磁共振（NMR）、傅里叶变换红外光谱（FTIR）和紫外（UV）光谱分析，对82B1的结构进行了鉴定，确定其为7,13,14 -三羟基- 6h -苯并-[c]-铬-6-one8-[1′β-羧基环戊烷]-2′β-[8′β-乙基环戊烷]。其亚抑制浓度显著抑制白色念珠菌的主要毒力因子，如酵母对菌丝转化、生物膜形成和水解酶的分泌。它对人肝母细胞瘤细胞系（HepG2细胞）没有细胞毒性，这表明它有可能成为抗念珠菌药物开发的候选药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Microbiology 生物-微生物学

CiteScore

4.80

自引率

3.80%

发文量

380

审稿时长

2.5 months

期刊介绍： Current Microbiology is a well-established journal that publishes articles in all aspects of microbial cells and the interactions between the microorganisms, their hosts and the environment. Current Microbiology publishes original research articles, short communications, reviews and letters to the editor, spanning the following areas: physiology, biochemistry, genetics, genomics, biotechnology, ecology, evolution, morphology, taxonomy, diagnostic methods, medical and clinical microbiology and immunology as applied to microorganisms.